Novavax, Inc.
Viés de alta

[NVAX] Novavax: Update - 1.6 billion funded!

I still believe NVAX has a lot of potential and I'll say it again. My idea is clear that its NanoParticle and Matrix-M Adjuvant tech makes it a prime candidate for a COVID-19 vaccines. Even if it doesn't make it first (or ever), it still has major potential for the seasonal influenza (w/ NanoFlu) and its Respiratory Syncytial Virus (RSV) vaccine. Check out my original post that is linked.


Today's News:
1. cnbc.com/2020/07/07/novavax-sees-revenue-opportunities-from-potential-coronavirus-vaccine.html
2. fool.com/investing/2020/07/07/novavax-awarded-16-billion-from-operation-warp-spe.aspx
Beyond Technical AnalysisbiopharmabiopharmaceuticalsbiotechCoronavirus (COVID-19)covid-2019novavaxNVAXvaccine

Publicações relacionadas

Aviso legal